4️⃣ Finally, the enrichment of mesenchymal cancer cells and the change in the IC ligand repertoire towards CD80/CD155 predicts response to anti-PD-1/PD-L1 in cSCC, HNSCC & melanoma patient samples, revealing the importance of cancer cell heterogeneity as indicative of responsiveness

3️⃣ Epithelial cSCCs respond to anti-PD-1/L1 therapies, whereas mesenchymal cSCCs respond to anti-CTLA-4 and anti-TIGIT therapies. The anti-PD-L1/TIGIT combination is the most effective strategy for blocking the growth of cSCCs containing both epithelial and mesenchymal cancer cells

2️⃣ Using a cSCC model, we reveal that cancer cells change their IC ligand profile according to their epithelial/mesenchymal features, dictating the IC pathways involved in immune evasion: epithelial cancer cells via PD-1/L1 and mesenchymal cancer cells via CTLA-4/CD80 & TIGIT/CD155

Delighted to present our project on cell plasticity and immunotherapy resistance at the @irbbarcelona.bsky.social conference 'Molecular determinants of cancer therapy resistance'.

Wrapping up an incredible #ASEICACongress where I presented my recently published project on how cancer cell plasticity influences #immunotherapy response in skin tumors. Inspiring talks from colleagues and friends dedicated to #cancer research!